Alternative cell death of Apaf1-deficient neural progenitor cells induced by withdrawal of EGF or insulin

Biochim Biophys Acta. 2010 Mar;1800(3):405-15. doi: 10.1016/j.bbagen.2009.11.008. Epub 2009 Nov 13.

Abstract

Background: Various forms of cell death, such as apoptotic, autophagic and non-lysosomal types, are implicated in normal physiological processes. Apoptotic protease activating factor 1 (Apaf1) is an important component of the intrinsic apoptotic pathway. Deficiency of Apaf1 results in an accumulation of neural progenitor cells (NPCs) in the developing central nervous system and thus, in perinatal lethality. A small percentage of the mutant mice, however, are viable and grow to maturity. The occurrence of such normal mutants implicates alternative cell death pathways during neurogenesis.

Methods: NPCs prepared from wild-type or Apaf1-deficient embryos were cultured in growth factor-deprived medium and examined for cell death, caspase activation and morphological alterations. Generation of reactive oxygen species (ROS) and the effects of antioxidants were examined.

Results: Wild-type NPCs underwent apoptosis within 24 hours of withdrawal of epidermal growth factor (EGF) or insulin, whereas Apaf1-deficient NPCs underwent cell death but showed no signs of apoptosis. Autophagy was not necessarily accompanied by cell death. Cell death of the Apaf1-deficient NPCs resembled necroptosis-necrosis-like programmed cell death. The necroptosis inhibitor necrostatin-1, however, failed to inhibit the cell death. ROS accumulation was detected in NPCs deprived of growth factors, and an antioxidant partially suppressed the non-apoptotic cell death of Apaf1-deficient NPCs.

Conclusions: These data indicate that after withdrawal EGF or insulin withdrawal, the Apaf1-deficient cells underwent non-apoptotic cell death. ROS generation may partially participate in the cell death.

General significance: Non-apoptotic cell death in NPCs may be a compensatory mechanism in the developing CNS of Apaf1-deficient embryos.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Apoptosis / drug effects
  • Apoptotic Protease-Activating Factor 1 / deficiency*
  • Apoptotic Protease-Activating Factor 1 / genetics
  • Cell Death / drug effects
  • Cell Death / physiology*
  • Cell Division / drug effects
  • Crosses, Genetic
  • DNA Primers
  • Epidermal Growth Factor / pharmacology*
  • Genotype
  • Insulin / pharmacology*
  • Kinetics
  • Mice
  • Mice, Knockout
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / physiology*
  • Stem Cells / cytology
  • Stem Cells / drug effects
  • Stem Cells / physiology*
  • Thapsigargin / pharmacology
  • Tunicamycin / pharmacology

Substances

  • Antioxidants
  • Apaf1 protein, mouse
  • Apoptotic Protease-Activating Factor 1
  • DNA Primers
  • Insulin
  • Tunicamycin
  • Epidermal Growth Factor
  • Thapsigargin